We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+20.56%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$84.3M
AUM Growth
+$12.6M
Cap. Flow
+$1.91M
Cap. Flow %
2.26%
Top 10 Hldgs %
61.92%
Holding
37
New
10
Increased
7
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$5.48M
2
GILD icon
Gilead Sciences
GILD
+$3.8M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.43M
4
ACHC icon
Acadia Healthcare
ACHC
+$3.14M
5
NVRO
NEVRO CORP.
NVRO
+$2.69M

Top Sells

Rank Stock Value
1
HMSY
HMS Holdings Corp.
HMSY
+$4.83M
2
LLY icon
Eli Lilly
LLY
+$4.51M
3
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$2.97M
4
GSK icon
GSK
GSK
+$1.97M
5
FOLD
Amicus Therapeutics
FOLD
+$1.87M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$6.37B
$9.68M 11.48%
528,115
-92,219
-15% -$1.24M
MDT icon
2
Medtronic
MDT
$107B
$5.77M 6.84%
+65,036
New +$5.48M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.66B
$5.35M 6.35%
158,810
+71,630
+82% +$2.33M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$4.87M 5.78%
31,339
-2,352
-7% -$360K
UNH icon
5
UnitedHealth
UNH
$382B
$4.81M 5.7%
25,918
+526
+2% +$92.2K
BIO icon
6
Bio-Rad Laboratories Class A
BIO
$8.42B
$4.61M 5.47%
20,369
-2,344
-10% -$511K
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$4.53M 5.37%
60,893
+33,575
+123% +$2.69M
CNC icon
8
Centene
CNC
$31.3B
$4.46M 5.29%
111,704
-45,656
-29% -$1.72M
ACHC icon
9
Acadia Healthcare
ACHC
$3.17B
$4.08M 4.84%
82,694
+70,779
+594% +$3.14M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$4.05M 4.8%
401,909
-232,956
-37% -$1.87M
GILD icon
11
Gilead Sciences
GILD
$161B
$4.05M 4.8%
+57,157
New +$3.8M
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.58M 4.25%
+29,570
New +$3.43M
DGX icon
13
Quest Diagnostics
DGX
$25.1B
$3.42M 4.05%
30,754
-6,631
-18% -$701K
CLVS
14
DELISTED
Clovis Oncology, Inc.
CLVS
$3.03M 3.6%
32,385
+29,185
+912% +$1.79M
INGN icon
15
Inogen
INGN
$167M
$1.98M 2.35%
20,742
-11,651
-36% -$996K
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
$1.91M 2.26%
166,752
+127,056
+320% +$2.35M
GSK icon
17
GSK
GSK
$103B
$1.86M 2.21%
34,598
-37,014
-52% -$1.97M
TCMD icon
18
Tactile Systems Technology
TCMD
$620M
$1.74M 2.06%
+60,920
New +$1.37M
SGYP
19
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.66M 1.97%
372,694
-719,074
-66% -$2.97M
DRRX
20
DELISTED
DURECT Corp
DRRX
$1.64M 1.94%
+104,847
New +$1.19M
NBIX icon
21
Neurocrine Biosciences
NBIX
$17.7B
$1.56M 1.86%
+34,030
New +$1.65M
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$1.49M 1.76%
+12,210
New +$1.42M
AERI
23
DELISTED
Aerie Pharmaceuticals
AERI
$1.34M 1.59%
25,464
-23,336
-48% -$1.09M
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$611M
$971K 1.15%
61,405
-36,326
-37% -$528K
NTRA icon
25
Natera
NTRA
$37.5B
$693K 0.82%
+63,811
New +$623K
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Asymmetry Capital Management held 37 positions worth $84.3M, up 18% from $71.7M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Asymmetry Capital Management's Q2 2017 filing shows 10 new, 7 increased, 11 reduced and 9 closed positions. Its largest new stake was Medtronic: 65,036 shares worth $5.77M. The largest sale was HMS Holdings Corp., an estimated $4.83M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier, followed by Industrials.

  • Asymmetry Capital Management's largest Q2 2017 buy was Medtronic: 65,036 shares worth $5.77M.
  • Asymmetry Capital Management added most to Acadia Healthcare in Q2 2017, an estimated $3.14M increase.
  • Asymmetry Capital Management's biggest Q2 2017 reduction was Synergy Pharmaceuticals, Inc Common Stock, cutting an estimated $2.97M.
  • Asymmetry Capital Management fully exited HMS Holdings Corp. in Q2 2017, selling an estimated $4.83M.
  • Asymmetry Capital Management's ten largest holdings make up 62% of its $84.3M portfolio in Q2 2017.
  • Asymmetry Capital Management opened 10 new positions and closed 9 in Q2 2017.
  • Asymmetry Capital Management's portfolio value rose 18% quarter-over-quarter to $84.3M.

Based on Asymmetry Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.